PFG Investments LLC bought a new position in shares of Dominari Holdings Inc. (NASDAQ:DOMH - Free Report) in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 141,508 shares of the company's stock, valued at approximately $566,000. PFG Investments LLC owned about 1.30% of Dominari at the end of the most recent quarter.
Separately, Renaissance Technologies LLC lifted its holdings in shares of Dominari by 20.0% in the 4th quarter. Renaissance Technologies LLC now owns 56,326 shares of the company's stock worth $55,000 after buying an additional 9,400 shares during the period. Hedge funds and other institutional investors own 42.48% of the company's stock.
Analyst Upgrades and Downgrades
Separately, Wall Street Zen lowered Dominari from a "hold" rating to a "sell" rating in a research note on Thursday, May 22nd.
Read Our Latest Stock Report on DOMH
Dominari Trading Down 5.9%
Shares of NASDAQ:DOMH traded down $0.35 during trading on Friday, reaching $5.55. The stock had a trading volume of 168,175 shares, compared to its average volume of 1,083,099. The firm's 50-day simple moving average is $5.12 and its 200 day simple moving average is $4.38. Dominari Holdings Inc. has a one year low of $0.83 and a one year high of $13.58. The company has a market capitalization of $81.25 million, a P/E ratio of -1.23 and a beta of 0.57.
Dominari (NASDAQ:DOMH - Get Free Report) last announced its earnings results on Tuesday, April 15th. The company reported $0.20 earnings per share (EPS) for the quarter. Dominari had a negative return on equity of 91.67% and a negative net margin of 167.73%. The company had revenue of $6.56 million for the quarter.
Dominari Profile
(
Free Report)
Dominari Holdings Inc, a biotechnology company, focuses on developing small-molecule anticancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia.
Further Reading
Before you consider Dominari, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Dominari wasn't on the list.
While Dominari currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
